Pediatric data add to Shire's ADHD package

Shire plc (LSE:SHP; NASDAQ:SHPG) said its SHP465 triple-bead mixed amphetamine salts (MAS) met the primary endpoint of improving ADHD symptoms in the Phase

Read the full 236 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE